Brevan Howard Capital Management
ITCI icon

Brevan Howard Capital Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Brevan Howard Capital Management’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-8,011
Closed -$669K – 1541
2024
Q4 		$669K Sell
8,011
-6,423
-44% -$528K ﹤0.01% 536
2024
Q3 		$1.06M Sell
14,434
-9,184
-39% -$690K 0.01% 439
2024
Q2 		$1.62M Buy
23,618
+18,750
+385% +$1.3M 0.01% 240
2024
Q1 		$337K Buy
4,868
+1,829
+60% +$126K ﹤0.01% 607
2023
Q4 		$218K Buy
+3,039
New +$175K ﹤0.01% 860

Other funds holding ITCI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Pentwater Capital Management
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
HBK Investments
HBK Investments Dallas, Texas $10.3B AUM 67.69% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Davidson Kempner Capital Management
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
UBS O'Connor
UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return
Farallon Capital Management
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Brevan Howard Capital Management's ITCI Position: Q1 2025 in Review

Brevan Howard Capital Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2025, closing a stake of 8,011 shares — an estimated $669K sold.

Brevan Howard Capital Management first reported a position in ITCI in Q4 2023 and held it in 5 quarters. The position peaked at $1.62M in Q2 2024. 395 funds tracked by Wall St. Rank hold ITCI as of Q1 2025.

  • Brevan Howard Capital Management reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2025 after selling out during the quarter.
  • Brevan Howard Capital Management sold 8,011 Intra-Cellular Therapies Inc. shares in Q1 2025, an estimated $669K.
  • Brevan Howard Capital Management first reported a position in Intra-Cellular Therapies Inc. in Q4 2023 and held it in 5 quarters.
  • Brevan Howard Capital Management's Intra-Cellular Therapies Inc. position peaked at $1.62M in Q2 2024.
  • 395 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2025.

Based on Brevan Howard Capital Management's 13F filing for Q1 2025, filed 15 May 2025.